Literature DB >> 29500121

Cardiovascular and renal burdens of prediabetes in the USA: analysis of data from serial cross-sectional surveys, 1988-2014.

Mohammed K Ali1, Kai McKeever Bullard2, Sharon Saydah2, Giuseppina Imperatore2, Edward W Gregg2.   

Abstract

BACKGROUND: There is controversy over the usefulness of prediabetes as a diagnostic label. Using data from US National Health and Nutrition Examination Surveys (NHANES) between 1988 and 2014, we examined the cardiovascular and renal burdens in adults with prediabetes over time and compared patterns with other glycaemic status groups.
METHODS: We analysed cross-sectional survey data from non-pregnant adults aged 20 years and older from the NHANES survey periods 1988-94, 1999-2004, 2005-10, and 2011-14. We defined diagnosed diabetes as patients' self-report that they had been previously diagnosed by a physician or health professional; among those with no self-reported diabetes, prediabetes was defined as a fasting plasma glucose (FPG) concentration of 100-125 mg/dL (5·6-6·9 mmol/L) or an HbA1c of 5·7-6·4% (39-47 mmol/mol); undiagnosed diabetes as an FPG of 126 mg/dL (7·0 mmol/L) or higher or an HbA1c of 6·5% (48 mmol/mol) or higher; and normal glycaemic status as an FPG of less than 100 mg/dL (5·6 mmol/L) and an HbA1c of less than 5·7% (39 mmol/mol). We repeated the analyses using varying definitions of prediabetes (FPG 110-125 mg/dL [6·1-6·9 mmol/L] or HbA1c 5·7-6·4% [39-47 mmol/mol], FPG 110-125 mg/dL [6·1-6·9 mmol/L] or HbA1c 6·0-6·4% [42-47 mmol/mol], and FPG 100-125 mg/dL [5·6-6·9 mmol/L] and HbA1c 5·7-6·4% [39-47 mmol/mol]). For each group over time, we estimated the prevalences of hypertension and dyslipidaemia; and among individuals with those conditions, we estimated the proportions who had been treated and who were achieving care goals. By glycaemic group, we estimated those who were current, former, and never smokers; mean 10-year risk of cardiovascular disease (using estimators from the Framingham Heart Study, the United Kingdom Prospective Diabetes Study (UKPDS), and the ACC/AHA ASCVD guidelines); albuminuria (median and albumin-to-creatinine ratio ≥30 mg/g), estimated glomerular filtration rate (eGFR; mean and <60 mL/min per 1·73m2); and prevalence of myocardial infarction and stroke. For all estimates, we calculated predicted changes between 1988-94 and 2011-14 using logistic regression models adjusted for age, sex, and race or ethnic group.
FINDINGS: We obtained data for 27 971 eligible individuals. In 2011-14, in the population of adults with prediabetes, 36·6% (95% CI 32·8-40·5) had hypertension, 51·2% (47·0-55·3) had dyslipidaemia, 24·3% (21·7-27·3) smoked; 7·7% (6·8-8·8) had albuminuria; 4·6% (3·7-5·9) had reduced eGFR; and 10-year cardiovascular event risk ranged from 5% to 7%. From 1988-94 to 2011-14, adults with prediabetes showed significant increases in hypertension (+9·7 percentage points [95% CI 5·4-14·0]); no change in dyslipidaemia; decreases in smoking (-6·4 percentage points [-10·7 to -2·1]); increased use of treatment to lower blood pressure (54·2% [49·0-59·3] to 81·4% [76·7-85·3], +27·2 percentage points [20·5-33·8] p<0·0001) and to reduce lipids (6·6% to 40·2%, +33·6 percentage points [30·2-37·0], p<0·0001); and increased goal achievements for blood pressure (25·8% to 62·0%, +36·2 percentage points [30·7-41·8], p<0·0001) and lipids (1·0% to 32·8%, +31·8 percentage points [29·1-34·4, p<0·0001]). People with prediabetes also showed decreases in cardiovascular risk (ASCVD -1·9 percentage points [-2·5 to -1·3] to UKPDS -2·7 [-3·5 to -1·9], p<0·0001); but no change in prevalence of albuminuria, reduced eGFR, myocardial infarction, or stroke. Prevalence and patterns were consistent across all prediabetes definitions examined. Compared with adults with prediabetes, adults with diagnosed diabetes showed much larger improvements in cardiovascular and renal risk treatments, apart from smoking, which did not decline.
INTERPRETATION: Over 25 years, cardiovascular and renal risks and disease have become highly prevalent in adults with prediabetes, irrespective of the definitions used. Identification of people with prediabetes might increase the opportunity for cardiovascular and renal risk reduction. FUNDING: None.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29500121      PMCID: PMC6615033          DOI: 10.1016/S2213-8587(18)30027-5

Source DB:  PubMed          Journal:  Lancet Diabetes Endocrinol        ISSN: 2213-8587            Impact factor:   32.069


  46 in total

Review 1.  Advancing Measurement of Diabetes at the Population Level.

Authors:  Mohammed K Ali; Karen R Siegel; Michael Laxy; Edward W Gregg
Journal:  Curr Diab Rep       Date:  2018-09-19       Impact factor: 4.810

2.  Dynamic Glucose Disposal is Driven by Reduced Endogenous Glucose Production in Response to Voluntary Wheel Running: A Stable Isotope Approach.

Authors:  Timothy D Allerton; Greg Kowalski; Hardy Hang; Jacqueline Stephens
Journal:  Am J Physiol Endocrinol Metab       Date:  2020-04-28       Impact factor: 4.310

3.  Trends in Self-reported Prediabetes and Metformin Use in the USA: NHANES 2005-2014.

Authors:  Caroline Liu; Kathryn Foti; Morgan E Grams; Jung-Im Shin; Elizabeth Selvin
Journal:  J Gen Intern Med       Date:  2019-10-21       Impact factor: 5.128

Review 4.  Prevention of Diabetes Mellitus in Patients With Prediabetes.

Authors:  Nicholas W Carris; Ronald R Magness; Arthur J Labovitz
Journal:  Am J Cardiol       Date:  2018-11-06       Impact factor: 2.778

5.  Prediabetes and Risk for Cardiovascular Disease by Hypertension Status in Black Adults: The Jackson Heart Study.

Authors:  Demetria Hubbard; Lisandro D Colantonio; Rikki M Tanner; April P Carson; Swati Sakhuja; Byron C Jaeger; Robert M Carey; Laura P Cohen; Daichi Shimbo; Mark Butler; Alain G Bertoni; Aisha T Langford; John N Booth; Jolaade Kalinowski; Paul Muntner
Journal:  Diabetes Care       Date:  2019-10-07       Impact factor: 19.112

Review 6.  Global pandemics interconnected - obesity, impaired metabolic health and COVID-19.

Authors:  Norbert Stefan; Andreas L Birkenfeld; Matthias B Schulze
Journal:  Nat Rev Endocrinol       Date:  2021-01-21       Impact factor: 43.330

7.  Patterns of changes in fasting plasma glucose, hemoglobin A1c and the area under the curve during oral glucose tolerance tests in prediabetic subjects: results from a 16-year prospective cohort study among first-degree relatives of type 2 diabetic patients.

Authors:  Shahla Safari; Masoud Amini; Ashraf Aminorroaya; Awat Feizi
Journal:  Acta Diabetol       Date:  2020-10-21       Impact factor: 4.280

8.  Effect of a Collaborative Care Model on Depressive Symptoms and Glycated Hemoglobin, Blood Pressure, and Serum Cholesterol Among Patients With Depression and Diabetes in India: The INDEPENDENT Randomized Clinical Trial.

Authors:  Mohammed K Ali; Lydia Chwastiak; Subramani Poongothai; Karl M F Emmert-Fees; Shivani A Patel; Ranjit Mohan Anjana; Rajesh Sagar; Radha Shankar; Gumpeny R Sridhar; Madhu Kosuri; Aravind R Sosale; Bhavana Sosale; Deepa Rao; Nikhil Tandon; K M Venkat Narayan; Viswanathan Mohan
Journal:  JAMA       Date:  2020-08-18       Impact factor: 56.272

9.  Effects of metformin on blood lipid profiles in nondiabetic adults: a meta-analysis of randomized controlled trials.

Authors:  Shuwei Weng; Yonghong Luo; Ziyu Zhang; Xin Su; Daoquan Peng
Journal:  Endocrine       Date:  2020-01-16       Impact factor: 3.633

Review 10.  Issues in Defining the Burden of Prediabetes Globally.

Authors:  Justin B Echouffo-Tcheugui; Andre P Kengne; Mohammed K Ali
Journal:  Curr Diab Rep       Date:  2018-09-19       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.